| 杨辰,刘芬菊,宋妙丽,仲汉彬,石燕.125I-脱氧尿嘧啶核苷-壳聚糖载药纳米微粒的研制和鉴定[J].中华放射医学与防护杂志,2010,30(6):650-653,700 |
| 125I-脱氧尿嘧啶核苷-壳聚糖载药纳米微粒的研制和鉴定 |
| Preparation and in vitro evaluation of chitosan nanoparticles containing 5-[125I]Iodo-2'-deoxyuridine |
| 投稿时间：2010-07-13 |
| DOI： |
| 中文关键词: 125I-UdR 纳米微粒 内照射治疗 |
| 英文关键词:125I-UdR Nanoparticle Inner radiotherapy |
| 基金项目:国家自然科学基金(30870585);江苏省卫生厅科技项目(Z200622) |
|
| 摘要点击次数: 3153 |
| 全文下载次数: 2187 |
| 中文摘要: |
| 目的 研制直径100～200 nm的125I-脱氧尿嘧啶核苷-壳聚糖载药纳米微粒( 125I-UdR-CS-DLN),并进一步分析其药物缓释性能和肿瘤靶向性。方法 采用离子交联法制备CS纳米微粒,以单因素分析和正交试验优化制备条件和工艺;用动态透析法分析其释放特性;激光共聚焦显微镜观察其肿瘤靶向性。结果 按照CS浓度1 g/L,搅拌速度600 r/min,TPP浓度2 g/L,相对分子质量为3×103的条件下得到平均粒径(70.39±5.12) nm的纳米微粒(PDI为0.16±0.012)。透射电镜观察其外观为规整的球形,大小均匀,分散度较好。在投药量为2.96 MBq/ml、pH值为5的条件下, 125I-UdR-CS-DLN的载药量1253.55 MBq/g,包封率42.35%,具有明显的缓释作用。激光共聚焦显微镜观察结果证明肿瘤细胞在2 h内摄入的纳米粒子明显多于正常细胞。结论 成功制备了直径为(127.81±15.25) nm (PDI 为0.240±0.035)的 125I-UdR-CS-DLN,确定了最佳工艺条件。所制备的纳米粒子具有典型的长效缓释制剂特性,并具有肿瘤细胞被动靶向性,为 125I-UdR应用于肿瘤内照射治疗提供了更有效的途径。 |
| 英文摘要: |
| Objective To prepare the chitosan nanoparticles loading 5-[125I]Iodo-2'-deoxyuridine ( 125I-UdR-CS-DLN) at 100-200 nm in diameter, and analyze the characteristic of drug sustained-releasing and tumor targeting. Methods Orthogonal experimental design and One-way analysis were applied to optimize the preparation of 125I-UdR-CS-DLN using tripolyphosphate cross-linking. Dynamic dialysis was utilized to investigate the in vitro releasing characteristics of the nanoparticles. The tumor targeting effect of the nanoparticles was observed with laser confocal microscopy. Results The optimal conditions for preparing the nanoparticles at particle diameters (70.39±5.12) nm (PDI 0.16±0.012) were 1 g/L of CS, 2 g/L of TPP, stirring rate 600 r/min, relative molecular mass of CS 3×103. The TEM results showed that the exterior of the nanoparticles was spheroid, with a uniform and fine dispersivity. The optimized condition with the initial 125I-UdR concentration of 2.96 MBq/ml at pH5 provided the highest loading capacity (1253.55 MBq/g) and the highest entrapment rate (42.35%). The in vitro releasing curves of 125I-UdR-CS-DLN followed Higuchi equation, shown a characteristic of long-acting preparation. Laser confocal microscopy observations approved that the tumor cells uptake of FITC-CS-nanoparticles were significantly more than that of normal cells. Conclusions Chitosan nanoparticles loading 125I-UdR at diameters range 127.81±15.25 nm(PDI 0.240±0.035) were successfully prepared with the optimized conditions, and showed a characteristic of sustained-releasing and tumor targeting. The chitosan-based nanotechnology provided a new and efficient approach for the application of 125I-UdR in intracellular radiotherapy for tumor. |
| HTML 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|